• Ashish Y. Pawar MGV’s Pharmacy College, Panchavati, Nashik 422003 State-Maharashtra, India
  • Snehal H. Patil MGV’s Pharmacy College, Panchavati, Nashik 422003 State-Maharashtra, India
  • Khanderao R. Jadhav MGV’s Pharmacy College, Panchavati, Nashik 422003 State-Maharashtra, India
  • Sandip R. Baviskar MGV’s Pharmacy College, Panchavati, Nashik 422003 State-Maharashtra, India


Objective: The sustained release of drug from the dosage form is useful especially for achieving controlled plasma level of the drug as well as improving bioavailability. The objective of the present work was to release matrix tablet of Venlafaxine HCl by using directly compressible co-processed Excipient.

Methods: Co-processed excipient (Chitosan 88%: eudragit s-100) was prepared in the ratio of 1:1, 1:3, and 1:5 by the solvent evaporation method. The sustained release matrix tablets were prepared by using Co-processed excipient by direct compression and formulate formulations such as F1to F9. The tablets evaluated for various physical parameters. Direct compression method followed by optimization of the evaluation parameters was employed to get the final optimized formulation.

Results: The developed Co-processed excipient was characterized for DSC, FTIR, SEM and XRD which confirm the absence of any chemical changes during co-processing. Co-processed excipient prepared in the ratio of 1:5 showed excellent flow properties. Among all formulations, Optimized formulation F9 showed the desired release profile 98.7% for a period of 24 h in phosphate buffer (pH 7.4). The release co-efficient values ‘n' (>0.5) indicated that the drug release followed non fickian anomalous mechanism based on formulation factors. Developed formulations were kept for stability study for three month as per ICH guidelines and found to be stable

Conclusion: Developed co-processed excipient showed good drug release retarding property and could be alternate way to overcome the problems associated with single polymer alone. Venlafaxine HCl matrices could be developed with desirable release modulation for a once daily administration.

Keywords: Co-processed excipient, Sustained release, Matrix tablet, Chitosan 88%, Eudragit s-100, Venlafaxine Hydrochloride.


Download data is not yet available.


1. Russell R. Synthetic excipient challenge all-natural organics offer advantages challenges to developer and formulators. Pharm Tech 2004;27:38-50.
2. The International Pharmaceutical Excipient Council Excipient Composition Guide. Europe: 2009.
3. Bansal AK, Nachaegari SK. Co-processed excipient for solid dosage form. Pharm Technol 2004;2:52-64.
4. Ogaji IJ, Nep EI, Peter JD. Advances in natural polymers as pharmaceutical excipients. Pharm Anal Acta 2012;3:146.
5. Ayyapan J, Umapathi P. Development and evaluation of a directly compressible Co-processed sustained release agent for tablets. Int J Pharm Sci 2010;2:201-5.
6. Panda B, Raot A, Kilor V. Co-processed excipients: an overview of formulation aspects, physical characteristics& role as a pharmaceutical aid. Pharmatutor-Art1049; 2010.
7. MH Rubinstein. Tablets. In: AULTON ME. (Ed). Pharmaceutics: the science of dosage form design. London: ELBS Longman Group Ltd; 1988. p. 304-21.
8. George M, Abraham ET. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review. J Control Release 2006;114:1–14.
9. Sanford PA. Chitosan: commercial uses and potential applications; 1989. p. 51-69.
10. Meenakshi joshi. Role of eudragit in targeted drug delivery. Int J Curr Pharm Res 2013;5:57-62.
11. Moustafine RI, Kemenova VA, van den Mooter G. Characteristics of interpolyelectrolyte complexes of Eudragit E 100 with sodium alginate. Int J Pharm 2005;294(1-2):113–20.
12. British Pharmacopoeia Published by The Department of Health, United Nations, Volume II, Venlafaxine Hydrochloride; 2009. p. 6317-20.
13. Raju G. Formulation and evaluation of extended release matrix tablets of venlafaaxine hydrochloride. J Adv Pharm Sci 2012;2(1):240-65.
14. Gohel MC, Jogani PD. A review of co-processed directly compressible excipients. J Pharm Sci 2005;8(1):76-92.
15. Coates J. Interpretation of infrared spectra, a practical approach. John Wiley & Sons Ltd, Chichester, Meyers RA, editors. Encycl Anal Chem 2000. p. 10815–37.
16. Skoog DA, Holler F, Nieman S. Principles of instrumental analysis. Fifth Edition: Thomson Asia Pvt. Limited Singapore; 1996. p. 410-3.
17. Anthony CM, Osselton MD, Widdop B. editors. Clark’s Analysis of Drugs and Poisons. Pharmaceutical press Publication: Third Edition; 2005;2: p 598.
18. Higuchi T. Mechanism of sustained action medication. theoretical analysis of rate of release of solid drug dispersed in solid matrices. J Pharm Sci 1963;52:1145-9.
19. Korsmeyer RW, Meerwal E, Peppas NA. Solute and penetrant diffusion in swellable polymers. ii. verification of theoretical models. J Polym Sci Polym Phys Ed 1986;24:409-34.
20. Cartensen JT. Drug stability: principle and practices, edited by Marcel Dakker, 2nd ed. New York; 1999. p. 538-50.
355 Views | 1334 Downloads
How to Cite
Pawar, A. Y., S. H. Patil, K. R. Jadhav, and S. R. Baviskar. “FORMULATION AND EVALUATION OF MATRIX TABLET OF VENLAFAXINE HCL BY USING DIRECTLY COMPRESSIBLE CO-PROCESSED EXCIPIENT”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 6, no. 10, 1, pp. 504-11,
Original Article(s)